Table 1: Baseline characteristics of the
patients with and without CSPH.
|
|
non-CSPH
cohort |
CSPH
cohort |
P value |
|
Age, year |
69.0 ± 7.5 |
67.2 ± 8.2 |
0.46 |
|
Sex, female/male |
46/41 |
19/7 |
0.47 |
|
BMI, kg/m2 |
23.6 ± 3.7 |
23.6 ± 3.6 |
0.87 |
|
White blood cellｓ, 103/dL |
39.6 ± 13.6 |
35.2 ± 10.9 |
0.18 |
|
Hemoglobin, g/dL |
13.1 ± 1.4 |
11.6 ± 1.7 |
< 0.001 |
|
Platelets, 103/μL |
79.0 ± 15.4 |
65.2 ± 21.6 |
0.003 |
|
PT INR |
1.14 ± 0.10 |
1.26 ± 0.11 |
< 0.001 |
|
Albumin, g/dL |
3.8 ± 0.3 |
3.0 ± 0.3 |
< 0.001 |
|
Total bilirubin, mg/dL |
1.0 ± 0.3 |
1.5 ± 0.5 |
0.02 |
|
AST, IU/L |
80.8 ± 48.1 |
90.7 ± 61.9 |
0.60 |
|
ALT, U/L |
76.4 ± 46.6 |
59.8 ± 36.6 |
0.08 |
|
eGFR,
mL/min |
68.2 ± 12.8 |
75.5 ± 18.3 |
0.006 |
|
AFP, ng/mL |
44.1 ± 77.0 |
37.0 ± 60.5 |
0.44 |
|
CTP score |
5.3 ± 0.5 |
7.5 ± 0.5 |
0.005 |
|
MELD score |
5.3 ± 3.7 |
6.6 ± 3.6 |
0.007 |
|
History of Acites,
no. (%) |
1 (1%) |
11 (42%) |
< 0.001 |
|
History of HCC, no. (%) |
29 (33.3%) |
12 (46.2%) |
0.33 |
|
HCV genotype |
|||
|
1b, no. (%) |
78 (89.7%) |
24 (92.3%) |
|
|
2, no. (%) |
9 (10.3%) |
2 (7.7%) |
|
|
HCV viral load, log10
IU/mL |
5.9 ± 0.9 |
5.7 ± 0.6 |
0.10 |
|
Previous HCV Treatment, no. (%) |
39 (44.8%) |
9 (34.6%) |
0.36 |
|
SVR12, % (n/n) |
93.1% (81/87) |
96.2% (25/26) |
0.57 |
|
Serious AE, no. (%) |
0 |
2(7.7%)† |
0.009 |
|
Discontinuation of treatment |
0 |
0 |
- |
†One
with pneumonia and the other with cryptogenic bacteremia.
AE: Adverse Event; BMI: Body Mass Index; CTP: Child-Turcotte-Pugh; CSPH: Clinically Significant Portal
Hypertension; eGFR: Estimated Glomerular Filtration
Rate calculated with the use of the Cockroft-Gault
equation; HCC: Hepatocellular Ccarcinoma; MELD: Model
for End-stage Liver Disease; PT INR: Prothrombin
International Normalized Ratio; SVR: Sustained Virological
Response